Objective: To identify the main active components in Shenbing decoction Ⅲ and their targets and explore the mechanism by which Shenbing decoction Ⅲ alleviates proteinuria in chronic kidney disease (CKD) based on network pharmacology.
Methods: The active components of Shenbing decoction Ⅲ and their potential targets, along with the oral bioavailability and drug-like properties of each component were searched in the TCMSP database. The proteinuria-related targets were searched in the GeneCards database. The active component-target network was constructed using Cytoscape software, and the acquired information of the targets from ClueGO was used for enrichment analysis of the gene pathways.
Results: A total of 102 active components were identified from Shenbing decoction Ⅲ. These active components acted on 126 targets, among which 69 were related to proteinuria. Enrichment analysis revealed fluid shear stress- and atherosclerosisrelated pathways as the highly significant pathways in proteinuria associated with CKD.
Conclusions: We preliminarily validated the prescription of Shenbing decoction Ⅲ and obtained scientific evidence that supported its use for treatment of proteinuria in CKD. The findings in this study provide a theoretical basis for further study of the mechanism of Shenbing decoction Ⅲ in the treatment of proteinuria in CKD.
目的: 基于网络药理学探讨肾病Ⅲ号方的主要活性成分、靶点及治疗慢性肾脏病蛋白尿的作用机制。
方法: 结合口服生物利用度和类药性，在TCMSP数据库中寻找与肾病Ⅲ号方组方中药相关的活性成分、靶点，在GeneCards数据库搜索蛋白尿相关靶点，采用Cytoscape软件构建活性成分-靶点网络，并将获取的靶点信息利用ClueGO进行基因通路的富集分析。
结果: 从肾病Ⅲ号方中筛选获得102个活性成分、作用于126个靶点，与蛋白尿相关的靶点69个，流体剪切应力和动脉粥样硬化相关通路显著性高。
结论: 初步验证了肾病Ⅲ号方的组方合理性及其治疗慢性肾脏病蛋白尿的科学性，并为进一步深入探讨肾病Ⅲ号方治疗慢性肾脏病蛋白尿的机制奠定理论基础。
Keywords: Shenbing decoction Ⅲ; chronic kidney disease; mechanism; network pharmacology; proteinuria.